Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation specific immunotherapies which are safe, effective and convenient. First generation treatments for food allergy aim to attenuate the immune response over time with repeated exposure to the whole allergen extracts. Because these extracts contain the same proteins that the patients are allergic to, therapy can trigger severe allergic reactions which drives the need for clinicians to implement significant risk mitigation measures. Furthermore, daily dosing is required indefinitely because sensitization to peanut returns quickly after cessation of therapy. Aravax applies proprietary technology and know-how to design highly targeted pharmacotherapies which reset the immune system to tolerate a specific allergen without evoking allergic reactions during treatment. The lead product, PVX108, is being developed for the treatment of peanut allergy and showed no evidence of triggering acute allergic reactions in Phase 1 clinical trials conducted in peanut-allergic adults. Furthermore, highly relevant changes to the peanut-specific immune response were observed 12 months following the cessation of treatment. Aravax has received FDA clearance for its IND application and Phase 2 clinical trials are underway in children with peanut allergy.